Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter studyFumihiko Urabe, Hiroki Yamada, Jun Miki et al.|International Journal of Urology|2024Cited by 20
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter studyTakafumi Yanagisawa, Takahiro Kimura, Wataru Fukuokaya et al.|The Prostate|2024Cited by 19
Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: Real-world data from a multicenter studyFumihiko Urabe, Takahiro Kimura, Kojiro Tashiro et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 11
Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter studyFumihiko Urabe, Takahiro Kimura, Shingo Hatakeyama et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 7
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Takahiro Kimura, Hirokazu Kagawa et al.|Prostate International|2024Cited by 6